retatrutide clinical trial results side effects VisualAbstract: reduces body weight by 17.5% in patients with obesity Unapproved weight loss drug retatrutide
Description
1 in 8 people worldwide are living with obesity
Additionally, treatment with GLP-1RAs was found to upregulate the expression of pulmonary surfactant proteins A and B, contributing to improved respiratory physiology (Wang et al., 2023b)

Demand for GLP-1 medicines used for weight loss has increased quickly

Overall, 74 percent of people on the drug reported stomach issues like nausea and vomiting
